Pituicytoma—An outlook on possible targeted therapies

Mende, Klaus Christian; Matschke, Jakob; Burkhardt, Till; Saeger, Wolfgang; Buslei, Rolf; Buchfelder, Michael; Fahlbusch, Rudolf; Westphal, Manfred; Flitsch, Jörg

doi:10.1111/cns.12709

Cited by 15 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A possible development of this tumor was also noticed from the FS cells. In a recent study, a positivity for vascular endothelial growth factor (VEGF) was detected in patients with pituicytoma (9).…”

Section: Trophic and Neurotrophic Factors In Human Pituitary Adenomasmentioning

confidence: 97%

Trophic and neurotrophic factors in human pituitary adenomas (Review)

Spoletini

Taurone

Tombolini

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

The pituitary gland is an organ that functionally connects the hypothalamus with the peripheral organs. The pituitary gland is an important regulator of body homeostasis during development, stress, and other processes. Pituitary adenomas are a group of tumors arising from the pituitary gland: they may be subdivided in functional or non-functional, depending on their hormonal activity. Some trophic and neurotrophic factors seem to play a key role in the development and maintenance of the pituitary function and in the regulation of hypothalamo-pituitary-adrenocortical axis activity. Several lines of evidence suggest that trophic and neurotrophic factors may be involved in pituitary function, thus suggesting a possible role of the trophic and neurotrophic factors in the normal development of pituitary gland and in the progression of pituitary adenomas. Additional studies might be necessary to better explain the biological role of these molecules in the development and progression of this type of tumor. In this review, in light of the available literature, data on the following neurotrophic factors are discussed: ciliary neurotrophic factor (CNTF), transforming growth factors β (TGF‑β), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), vascular endothelial growth inhibitor (VEGI), fibroblast growth factors (FGFs) and epidermal growth factor (EGF) which influence the proliferation and growth of pituitary adenomas.

show abstract

Section: Trophic and Neurotrophic Factors In Human Pituitary Adenomasmentioning

confidence: 97%

Trophic and neurotrophic factors in human pituitary adenomas (Review)

Spoletini

Taurone

Tombolini

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Some authors suggest that stereotactic segmentation or conventional radiotherapy should be used systematically to control the residual tumor following subtotal resection of tumors [40], while others suggest that these treatments are limited to smaller tumors that do not affect visual acuity [41], but further data are needed to prove the effect. Recently, Mende et al indicated strong immunostaining for vascular endothelial growth factor receptor (VEGF-R) in a small series of patients with pituicytomas [14]. Based on these results, anti-VEGF-R therapy (bevacizumab) and somatostatin analogs may be promising treatment options, although their use has not yet been approved.…”

Section: Treatments and Outcomesmentioning

confidence: 99%

“…Pituicytoma, which is a low-grade neurogenic tumor (WHO I), is a very rare spindle-shaped astrocytic tumor that originates from the posterior lobe or stalk of the pituitary gland [9,10]. To date, only 4 articles have reported more than 6 cases of pituicytoma [11,12,13,14]. Thus, useful, detailed, and accurate information regarding the diagnosis and treatment of pituicytomas is di cult to obtain.…”

Section: Epidemiology and Clinical Characteristicsmentioning

confidence: 99%

Clinical features, radiological profiles, pathological features and surgical outcomes of pituicytomas: a report of 11 cases and a pooled analysis of individual patient data

Cheng

Nie

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Pituicytoma is an extremely rare low-grade glial tumor that is closely related to the neurohypophysis axis. Most studies of pituicytomas include only several cases. To better understand this disease, we reviewed a series of cases of pituicytomas. The diagnosis and treatment of pituicytoma must be further elucidated.Methods: Eleven patients with pituicytoma admitted to Beijing Tiantan Hospital from 2012 to 2019 were selected. The clinical features, including radiological and histological examination, surgical records and prognosis were reviewed. Sixty-eight other previously published cases of pituicytoma also were used to analyze the predictive factors for the results.Results: Our cohort included 4 males (36.37%) and 7 females (63.63%), with a mean age of 48.6 years. The tumor was located in the suprasellar region in 4 patients (36.37%), intrasellar region in 5 patients (45.45%), and intrasellar-suprasellar region in 2 patients (18.18%). All patients were misdiagnosed with other common tumors in the sellar region before the operation. During the operation, gross total resection of the tumor was achieved in 6 patients (54.55%), and subtotal resection was achieved in 5 patients (45.45%). The mean progression-free survival time was 33.72 months. Tumor progression after surgical resection occurred in 4 patients (36.37%). Among them, 72.73% of the patients with subtotal resection experienced progression, while 18.18% of the patients with gross total resection experienced progression. Combined with the 68 cases in the literature, gross total resection was an independent risk factor for progression-free survival time (P<0.05).Conclusion: Pituicytomas are more common in middle-aged people and in the sellar region. The clinical manifestations of pituicytomas are different, but no diagnostic clinical features have been identified other than an abnormally abundant blood supply. Currently, gross total resection is the best approach for the treatment of pituicytomas. More patients and longer follow-up periods were needed to further elucidate the biological features of pituicytomas.

show abstract

“…Pituicytoma, which is a low-grade neurogenic tumor (WHO I), is a very rare spindle-shaped astrocytic tumor that originates from the posterior lobe or stalk of the pituitary [9,10]. Until now, only 4 articles have reported more than 6 cases of pituicytoma [11][12][13][14]. This makes it challenging to obtain useful, detailed, and accurate information regarding the diagnosis and treatment of pituicytomas.…”

Section: Epidemiology and Clinical Characteristicsmentioning

confidence: 99%

“…Some authors suggest that stereotactic segmentation or conventional radiotherapy should be used systematically to control tumor residue during subtotal resection of tumors [35], while others suggest that these treatments are limited to smaller tumors that do not affect visual acuity [36], but further data are needed to prove the effect. Recently, Mende et al has proved strong immunostaining of vascular endothelial growth factor receptor (VEGF-R) in a small series of pituicytoma [14]. Based on these results, anti-VEGF-R therapy (bevacizumab) and somatostatin analogues may be a promising treatment option, although its use has not yet been approved.…”

Section: Treatments and Outcomesmentioning

confidence: 99%

Clinical Features, Radiological Profiles, Pathological Features and Surgical Outcomes of Pituicytomas: A Report of 16 Cases and a Pooled Analysis of Individual Patient Data

Cheng

Nie

Bin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Pituicytomas are rare neurogenic tumors of the sellar region.The diagnosis and treatment of pituicytoma needs to be further elucidated.Patients and Methods: This research included 16 patients with pituicytomas that were pathologically diagnosed in Tiantan Hospital from 2012 to 2019. And 68 other previously published cases of pituicytoma to analyze the predictive factors of the results.Results: Our cohort included 7 males (43.75%) and 9 females (56.25%), with a mean age of 49 years. The tumor was located in the suprasellar in 7 cases (43.75%), intrasellar in 6 cases (37.5%), and intrasellar-suprasellar mixed in 3 cases (18.75%). All patients were misdiagnosed with other common tumors in the sellar region before the operation. During the operation, gross total resection (GTR) of the tumor was achieved in 9 cases (56.25%) and subtotal resection (STR) in 7 cases (43.75%). The mean progression-free survival time (PFS) was 34.63 months. Tumor progression after surgical resection occurred in 5 patients (31.25%). Among them, 57.14% of the patients with STR had progression, while 11.11% of the patients with GTR had progression. Combined with 68 cases in the literature, it was found that GTR was an independent risk factor for PFS(P<0.05). Conclusions: Pituicytomas are more common in middle-aged people and the suprasellar region. The clinical manifestations of pituicytomas are different, there are no diagnostic clinical features, and its blood supply is abnormally abundant. Currently, GTR is the best approach for the treatment of pituicytomas.

show abstract

Pituicytoma—An outlook on possible targeted therapies

Cited by 15 publications

References 24 publications

Trophic and neurotrophic factors in human pituitary adenomas (Review)

Trophic and neurotrophic factors in human pituitary adenomas (Review)

Clinical features, radiological profiles, pathological features and surgical outcomes of pituicytomas: a report of 11 cases and a pooled analysis of individual patient data

Clinical Features, Radiological Profiles, Pathological Features and Surgical Outcomes of Pituicytomas: A Report of 16 Cases and a Pooled Analysis of Individual Patient Data

Contact Info

Product

Resources

About